Table of Content

1 Introduction
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 INCLUSIONS & EXCLUSIONS
           1.3.3 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 Research Methodology 
    2.1 Research Data
           2.1.1 Secondary Sources
                    2.1.1.1 Key data from secondary sources
           2.1.2 Primary Sources
                    2.1.2.1  Key data from primary sources
    2.2 Market Size Estimation 
           2.1.1 Revenue Share Analysis
           2.1.2 Illustrative Figure of Revenue Share Analysis
    2.3 Market Breakdown And Data Triangulation
    2.4 Market Share Estimation
    2.5 Assumptions For The Study

3 Executive Summary 

4 Premium Insights 

5 Market Overview 
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
           5.2.2 Restraints
           5.2.3 Opportunities
           5.2.4 Challenges
    5.3 Market Trends
    5.4 Ranges/Scenario
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS/YC-YCC Shift
    5.6 Indicative Pricing Model Analysis 
    5.7 Value Chain Analysis
    5.8 Supply chain analysis
    5.9 Ecosystem Analysis
    5.10 Technology Analysis
    5.11 Patent analysis
    5.12 Key conferences & events in 2022-23
    5.13 Regulatory Landscape
    5.14 Regulatory bodies, government agencies and other organizations
    5.15 Porter's Five Forces Analysis
    5.16 Key stakeholders and buying criteria

6 Oligonucleotide synthesis Market, by product
    6.1 Introduction
    6.2 Oligonucleotide-based drugs
    6.3 Synthesized Oligonucleotides
           6.3.1 By Product
                    6.3.1.1 Primers
                    6.3.1.2 Probes
                    6.3.1.3 DNA Oligos
                    6.3.1.4 RNA Oligos
                    6.3.1.5 Other synthesized Oligos [Bridged nucleic acid (BNA), Locked nucleic acid (LNA)]
           6.3.2 By Type
                    6.3.2.1 Custom oligonucleotides
                    6.3.2.2 Predesigned oligos
    6.4 Reagents
    6.5 Equipment

7 Oligonucleotide synthesis Market, by application
    7.1 Introduction
    7.2 Therapeutic Applications
           7.2.1 By type
                    7.2.1.1 Antisense Oligonucleotide-based Therapies
                    7.2.1.2 siRNA Oligonucleotide-based Therapies
                    7.2.1.3 CpG Oligonucleotide-based Therapies
           7.2.2 By disease type
                    7.2.1.1 Neurological disorders
                    7.2.1.2 Infectious diseases
                    7.2.1.3 Other diseases (rare genetic diseases, cardiovascular diseases, cancer, inflammatory diseases, autoimmune disease)
    7.3 Diagnostic Applications
    7.4 Research Applications
           7.4.1 PCR
           7.4.2 Sequencing
           7.4.3 Other research applications (nucleic acid hybridization methods, microarrays, southern blotting methods)

8 Oligonucleotide synthesis Market, By End User
    8.1 Introduction
    8.2 Hospitals
    8.3 Pharmaceutical & Biotechnology companies
    8.4 Diagnostic Laboratories
    8.5 CROs & CMOs
    8.6 Academic Research Institutes

9 Oligonucleotide synthesis Market, By Region
    9.1 Introduction 
    9.2 North America 
           9.2.1 US
           9.2.2 Canada
    9.3 Europe 
           9.3.1 Germany
           9.3.2 France
           9.3.3 UK
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 RoE
    9.4 Asia Pacific
           9.4.1 Japan
           9.4.2 China
           9.4.3 India
           9.4.6 RoAPAC
           9.5.1 Latin America
           9.5.2 Brazil
           9.5.3 Mexico
           9.5.4 RoLATAM
    9.6 Middle East Africa

10 Competitive Landscape
     10.1 Introduction 
     10.2 Key Player Strategies/Right to Win
     10.3 Revenue Analysis
     10.4 Market Share Analysis
     10.5 Company Evaluation Quadrant
             10.5.1 Stars
             10.5.2 Emerging Leaders
             10.5.3 Pervasive Players
             10.5.4 Emerging Companies
             10.5.5 Participants
     10.6 Company Evaluation Quadrant: Start-ups/SMEs
     16.7 Competitive Benchmarking 
             16.7.1 DETAILED LIST OF KEY STARTUP/SMES
             16.7.2 COMPETITIVE BENCHMARKING OF key players [startups/smes]
     10.7 Competitive Scenario and Trends

11 Company Profiles
     11.1 Key Market Players
             11.1.1 Danaher Corporation (US)
             11.1.2 Thermo Fisher Scientific Inc. (US)
             11.1.3 Merck KGaA (Germany)
             11.1.4 LGC Limited (UK)
             11.1.5 Maravai Life Sciences (US)
             11.1.6 Agilent Technologies, Inc. (US)
             11.1.7 Eurofins Scientific (Germany)
             11.1.8 Kaneka Corporation (Japan)
             11.1.9 Biolegio B.V (Netherlands)
             11.1.10 Biolytic Lab Performance Inc. (US)
             11.1.11 Microsynth AG (Switzerland)
                        11.1.11.1 Other Players
             11.1.12 ATDBio Ltd. (UK)
             11.1.13 Twist Bioscience Corporation (US)
             11.1.14 Eton Bioscience, Inc. (US)
             11.1.15 CSBIO (US)
             11.1.16 Tag Copenhagen A/S (Denmark)
             11.1.17 Generi Biotech (Czech Republic)
             11.1.18 Biocomma Limited (China)
             11.1.19 Hongene Biotech Corporation (China)
             11.1.20 Hangzhou pharm &chem Co., Ltd (China)
             11.1.21 Tokyo Chemical Industry Co., Ltd. (Japan)
                        11.1.21.1 Therapeutic Market Players
             11.2.1 Biogen Inc. (US)
             11.2.2 Sarepta Therapeutics, Inc. (US)
             11.2.3 Ionis Pharmaceuticals, Inc. (US)
             11.2.4 Alnylam Pharmaceuticals, Inc. (US)

12 Appendix
     12.1 Discussion guide
     12.2 Knowledge Store: MarketsandMarkets' Subscription Portal
     12.3 Available Customisations
     12.4 Related Reports
     12.5 Author Details